Licensing
Pfizer Opts In On Neurological Target In Voyager Deal, Leaving $290 Million In Milestones
2022-10-05
AstraZeneca Blocks Ionis’ Hypercholesterolemia Treatment from Moving into a Phase 3 Study
2022-09-23
Takeda Throws $1 Million at F-star to Develop Bispecific Antibody For Novel Cancer Therapies
2022-07-21